A 67-year-old male presents to the primary care clinic for a routine follow-up. Five years… — USMLE Step 3

A $67$ -year-old male presents to the primary care clinic for a routine follow-up. Five years ago, he underwent a mechanical mitral valve replacement and has been maintained on chronic warfarin therapy. His target international normalized ratio (INR) is between $2.5$ and $3.5$ . Over the past year, his laboratory values have been stable on a daily warfarin dose of $5$ mg. Six days ago, he was evaluated at an urgent care facility for a suspected urinary tract infection and was prescribed a $7$ -day course of trimethoprim-sulfamethoxazole. The patient reports feeling well today. He denies any epistaxis, hematuria, melena, or easy bruising. Vital signs are within normal limits. Physical examination reveals clear lungs, normal heart sounds with a distinct mechanical click, and no petechiae or ecchymoses. His neurologic examination is unremarkable. A point-of-care INR obtained in the clinic today is $7.4$ . Which of the following is the most appropriate next step in management of this patient?

Withhold the next one to two doses of warfarin and recheck the laboratory values in $24$ to $48$ hoursAnswer
B
Administer oral phytonadione and withhold warfarin until the levels normalize
C
Administer four-factor prothrombin complex concentrate and intravenous phytonadione
D
Obtain an emergent non-contrast computed tomography scan of the head
E
Maintain the current medication regimen and advise the patient to strictly avoid vitamin K-rich foods

Answer

Withhold the next one to two doses of warfarin and recheck the laboratory values in

24

48

hours.

This patient has a supratherapeutic INR of

7.4

but remains completely asymptomatic without any signs of clinical bleeding. The acute elevation is due to the recent initiation of trimethoprim-sulfamethoxazole, a strong inhibitor of CYP2C9 that decreases the metabolism of S-warfarin. According to standard clinical guidelines, for patients with an INR between

4.5

and

10.0

and no evidence of bleeding, the recommended management is to simply withhold the next

1

2

doses of warfarin, monitor the INR closely, and restart therapy at an appropriately adjusted (lower) dose once the INR returns to the therapeutic range. Routine use of oral vitamin K is not recommended in this specific range due to the risk of overcorrection and subsequent warfarin resistance.

Step-by-Step Solution

Assess the patient's clinical stability and bleeding status.

The patient is completely asymptomatic with no signs of active bleeding or trauma on physical examination.

The presence or absence of major bleeding dictates whether rapid pharmacological reversal is required versus simple dose adjustment.

Evaluate the laboratory finding in the context of recent medication changes.

The INR is supratherapeutic at

7.4

, likely driven by the recent addition of trimethoprim-sulfamethoxazole.

Trimethoprim-sulfamethoxazole inhibits CYP2C9, significantly decreasing warfarin clearance and abruptly increasing the INR.

Apply clinical guidelines for warfarin management based on the INR value.

For an INR between

4.5

and

10.0

without bleeding, guidelines recommend withholding

1

2

doses of warfarin and rechecking the INR.

Routine use of vitamin K in this range is advised against because it can cause warfarin resistance once the patient needs to resume anticoagulation.

Key Concept

Management of supratherapeutic INR without bleeding

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic